Published reports have demonstrated both LGALS3 expression and binding capacity as independent poor prognostic markers in lung cancer patients (43), and treatment with an LGALS3 inhibitor was sufficient to reduce NSCLC tumor growth and metastasis in murine models (44). This evidence concerns the gene LGALS3 and neoplasm.